Nika Pharmaceuticals Discloses $2,932 in Cash, Reiterates Going Concern Warning, and Flags Ineffective Controls

summarizeSummary

Nika Pharmaceuticals' Q2 2026 filing reveals a cash balance of just $2,932, a going concern warning, and ineffective internal controls. The company has no revenue and relies on related-party loans to stay afloat.

check_boxKey Events · Earnings and Guidance · NIKA

• Cash Drops to $2,932

  Cash fell to $2,932 as of June 30, 2026, down from $1,889 at year-end 2025, while related-party debt rose to $340,624. The company has no revenue and a $9 million accumulated deficit.

• Going Concern Warning Reiterated

  Management again states substantial doubt about the company's ability to continue as a going concern, citing no income and reliance on related-party loans.

• Ineffective Internal Controls

  Disclosure controls were deemed ineffective due to material weaknesses: lack of an audit committee and lack of separation of duties.

• Net Loss of $33,054

  For the six months ended June 30, 2026, the company reported a net loss of $33,054, slightly higher than the $31,327 loss in the prior-year period.

auto_awesomeAnalysis · NIKA · Life Sciences

Nika Pharmaceuticals is running on fumes. Cash has dwindled to $2,932 against $340,624 in related-party debt, with no revenue and a $9 million accumulated deficit. The auditor's going concern warning is repeated, and management admits disclosure controls are ineffective due to a lack of an audit committee and separation of duties. The company is surviving on insider loans, but without a capital raise, it may not be able to continue operations. This filing confirms the financial distress first flagged in May, but the cash position has deteriorated further.